Pharmaceutical

CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma

The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.

Jul 30, 2024 - 04:00
CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma
The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.
Read the original article

Tags:

Previous Article

Bristol Myers Squibb reports dip in net income for Q2 2024

Next Article

New AI model boosts early osteoporosis diagnosis for ageing populations

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

STAT+: Biotech’s trade secrets face growing threat from...

Jun 6, 2023

Rituximab biosimilar by Celltrion for Waldenstrom Macro...

Nov 2, 2023

Pyxis cuts staff by 40% and pours resources into two cancer therapies

Pyxis cuts staff by 40% and pours resources into two ca...

Nov 8, 2023